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Summary
 
CD4 T helper (Th) type 1 and Th2 cells have been identified in the airways of asthmatic pa-
tients. Th2 cells are believed to contribute to pathogenesis of the disease, but the role of Th1
cells is not well defined. In a mouse model, we previously reported that transferred T cell re-
ceptor–transgenic Th2 cells activated in the respiratory tract led to airway inflammation with
many of the pathologic features of asthma, including airway eosinophilia and mucus produc-
tion. Th1 cells caused inflammation with none of the pathology associated with asthma. In this
report, we investigate the role of Th1 cells in regulating airway inflammation. When Th1 and
Th2 cells are transferred together into recipient mice, there is a marked reduction in airway
eosinophilia and mucus staining. To address the precise role of Th1 cells, we asked (i), Are
Th2-induced responses inhibited by interferon (IFN)-
 
g
 
? and (ii) Can Th1 cells induce eosino-
philia and mucus in the absence of IFN-
 
g
 
? In IFN-
 
g 
 
receptor
 
2
 
/
 
2
 
 recipient mice exposed to in-
haled antigen, the inhibitory effects of Th1 cells on both airway eosinophilia and mucus pro-
duction were abolished. In the absence of IFN-
 
g
 
 receptor signaling, Th1 cells induced mucus
but not eosinophilia. Thus, we have identified new regulatory pathways for mucus production;
mucus can be induced by Th2 and non-Th2 inflammatory responses in the lung, both of
which are inhibited by IFN-
 
g
 
. The blockade of eosinophilia and mucus production by IFN-
 
g
 
likely occurs through different inhibitory pathways that are activated downstream of Th2 cyto-
kine secretion and require IFN-
 
g
 
 signaling in tissue of recipient mice.
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A
 
sthma is a chronic inflammatory disorder of the airways
that is characterized by intermittent episodes of airway
obstruction and wheezing. Activation of CD4 Th2 cells in
the respiratory tract is now believed to be responsible, in part,
for pathogenesis in this disease. CD4 Th2 cells secreting
IL-4, IL-5, and IL-13 have been identified in the airways of
asthmatics (1–3). Th2 cytokines produced in the respiratory
tract lead to airway eosinophilia, high levels of serum IgE, and
mast cell activation (4), all believed to contribute to the patho-
 
logical consequences: airway hyperresponsiveness (AHR),
 
1
 
epithelial damage, and mucus hypersecretion.
Th1 cells have also been identified in the airways of asth-
matics, but their function is not clear (5, 6). One theory is
that Th1 cells protect against asthma (7). This is supported by
studies in allergic patients showing an increase in IFN-
 
g
 
 lev-
els after successful immunotherapy (8–10). IFN-
 
g
 
–dominated
immune responses to viral or mycobacterial infection in
childhood are associated with a reduced incidence of asthma
(11, 12). And, after infection with Bacillus Calmette-Guérin,
mice exhibited a reduction in eosinophilic airway inflam-
mation and AHR (13). Other studies suggest that Th1 cells
might potentiate the inflammatory response in asthma due
to the proinflammatory effects of Th1 cytokines (5, 14). A
shift in balance of cytokines from a dominant Th2 response
to a Th1 response may relieve or resolve symptoms, or, alter-
natively, worsen existing disease. The precise mechanisms
by which Th1 cells effect Th2 cell responses in the lung have
not been well characterized.
To investigate the role of Th1 or Th2 cells in airway dis-
ease, we developed a model in which highly skewed popu-
lations of Th1 or Th2 cells were activated in the respiratory
tract with inhaled antigen (15, 16). We showed that activation
of Th2 cells leads to airway eosinophilia, AHR, and mucus
hypersecretion, features consistent with human asthma. In
 
1
 
Abbreviations used in this paper:
 
 AHR, airway hyperresponsiveness; BAL,
bronchoalveolar lavage; HMI, histologic mucus index; PAS, periodic
acid-Schiff. 
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contrast, when activated in the lungs, Th1 cells caused inflam-
mation without the pathophysiologic characteristics of asthma.
We now address how Th1 cells regulate inflammation in
asthma. Using TCR-transgenic Th1 and Th2 cells generated
in vitro and transferred into recipient mice, we dissect the
mechanisms by which Th1 cells inhibit Th2-induced eosino-
philia and mucus production.
 
Materials and Methods
 
Mice.
 
DO11.10 mice, which are transgenic for the TCR rec-
ognizing OVA peptide 323–339 (pOVA
 
323–339
 
) (17), were provided
to us on a BALB/c background by Ken Murphy (Washington Uni-
versity, St. Louis, MO) and were bred in our facilities. IL-4–defi-
cient BALB/c mice (The Jackson Laboratory) were bred in our
facilities. Cells were transferred into 6–12-wk-old BALB/c mice
(The Jackson Laboratory) or IFN-
 
g
 
R
 
2
 
/
 
2
 
 mice (provided by J.
Aguet, Molecular Biology Institute, Zurich, Switzerland; back-
crossed six generations onto BALB/c).
 
Generation of Th1 or Th2 Cells.
 
To generate Th1 or Th2 cells
from DO11.10 mice, CD4 T cells were isolated by negative selec-
tion as previously described (18) using mAbs to CD8 (clone
53-6.72, clone 2.43; reference 19), class II MHC I-A
 
d
 
, and anti-
Ig–coated magnetic beads (Collaborative Research, Inc.). Naive
CD4 T cells were further isolated from this population by posi-
tive selection with a biotinylated anti–L-selectin antibody (Mel-14;
PharMingen) and streptavidin microbeads using MACS™
(Miltenyi Biotec). Syngeneic T cell–depleted splenocytes were
used as APCs and prepared by negative selection using antibodies
to CD4 (GK1.5; reference 20), anti-CD8, anti-Thy1 (21), and
treatment with rabbit complement. APCs were mitomycin-C
treated. To generate Th1 cells, cultures contained pOVA
 
323–339
 
at 5 
 
m
 
g/ml, IL-12 at 5 ng/ml (Genetics Institute), IL-2 at 10
U/ml (Collaborative Research, Inc.), and anti–IL-4 (11B11;
reference 22) at inhibitory concentration. To generate Th2 cells,
cultures contained pOVA
 
323–339 
 
at 5 
 
m
 
g/ml, IL-4 at 200 U/ml
(Collaborative Research, Inc.), IL-2 at 10 U/ml, and anti–IFN-
 
g
 
(XMG1.2; reference 23) at inhibitory concentration. All cultures
were set up in flasks containing equal numbers of CD4 T cells
and APCs at a final concentration of 5 
 
3
 
 10
 
5
 
 cells/ml and were
maintained for 4 d.
 
Transfer of Cells and Aerosol Administration of OVA.
 
Cultured
Th1- or Th2-like cells were harvested after 4 d and washed with
PBS, and cells were injected intravenously into syngeneic recipi-
ents. 1 d after transfer of cells, mice were challenged with inhaled 1%
OVA in PBS as previously described (15) for 20 min daily for a to-
tal of seven days over a period of nine days (four consecutive days
exposed, two days rested, and three consecutive days exposed).
Control mice received inhaled OVA only. Mice were analyzed
24 h after the final exposure to antigen.
 
Cytokine Assays.
 
At the time of transfer, an aliquot of Th1-
or Th2-like cells was retained for restimulation. 5 
 
3
 
 10
 
5
 
 CD4 T
cells/ml and 5 
 
3
 
 10
 
5
 
 freshly isolated BALB/c APCs per milliliter
were cultured with pOVA (5 
 
m
 
g/ml). Supernatants were collected
after 48 h. Bronchoalveolar lavage (BAL) cells obtained from in-
dividual mice were restimulated in vitro at 2 
 
3
 
 10
 
6
 
 cells/ml in
the presence of pOVA (5 
 
m
 
g/ml). IFN-
 
g
 
, IL-4, and IL-5 levels
from cell supernatants were determined by ELISA (Endogen).
Assays were standardized with recombinant IFN-
 
g
 
, IL-5, IL-10
(Endogen), and IL-4 (Collaborative Research, Inc.). The lower
limit of sensitivity for each of the ELISAs was 0.6 ng/ml (IFN-
 
g
 
),
5 pg/ml (IL-4), 0.010 ng/ml (IL-5), and 200 pg/ml (IL-10). For
BAL fluid cytokines, mice were exposed to aerosolized OVA on
days 1 and 2, BAL was performed on day 3, and fluid was analyzed
by ELISA for cytokines IL-4, IL-13 (R & D Systems, Inc.), IL-5
(Endogen), and IFN-
 
g
 
 (Biosource International, Inc.).
 
FACS™ Analysis.
 
Cell populations were stained with anti-
CD4 (Quantum Red-L3T4; Sigma Chemical Co.), the biotiny-
lated anticlonotypic antibody KJ1-26 (24), and FITC–avidin D
(Vector Labs.). KJ1-26 is specific for the transgenic TCR in the
DO11.10 mice. Th1 and Th2 cell populations transferred were
 
.
 
97% CD4 and KJ1.26 positive. After a period of inhalational ex-
posure, BAL cells were analyzed by FACS™ using these antibodies.
 
BAL.
 
BAL was performed by cannulation of the trachea and
lavage with 1 ml of PBS. Total cell counts were performed,
cytospin preparations of BAL cells were stained with Dif-Quik
(Baxter Healthcare Corp.), and differentials were performed
based on morphology and staining characteristics.
 
Lung Histology.
 
Lungs were prepared for histology by perfus-
ing the animal via the right ventricle with 20 ml of PBS. Lungs
were then inflated with 1.0 ml of fixative instilled through a tra-
cheostomy tube. Samples for paraffin sectioning were formalin
fixed and sectioned in the coronal plane at 5 
 
m
 
m, ensuring that
central airways were visible. Sections were stained with hematox-
ylin and eosin and periodic acid-Schiff (PAS). Histological mucus
index (HMI) was performed as previously described on PAS-
stained sections and is equivalent to the linear percent of epithe-
lium positive for mucus (15, 25). This index was calculated for
each mouse lung, and then the mean HMI was calculated for
each experimental group.
 
Results
 
Th1 Cells Inhibit Th2-induced Eosinophilia and Mucus Pro-
duction.
 
We previously showed that TCR-transgenic Th1
or Th2 cells generated in vitro and transferred into recipi-
ent mice are recruited to the lung after inhaled antigen
challenge and retain their polarized cytokine profile in vivo,
and that both Th1 and Th2 cells induce airway inflamma-
tion (15). Th2 cells stimulate inflammation with lympho-
cytes and eosinophils and induce airway epithelial mucus pro-
duction (Table I). Th1 cell activation leads to lymphocytic
inflammation, but Th1 cells fail to stimulate eosinophilia or
mucus production. It was unclear if the differences in Th1
and Th2 cell effects resulted from Th1 cells lacking the cyto-
kines necessary to induce eosinophilia and mucus or if Th1
cells actively inhibited these processes. To investigate the
mechanism by which Th1 cells failed to stimulate eosino-
 
Table I.
 
Effects of Th1 or Th2 Cell Activation in the
Respiratory Tract
 
Cells
transferred
BAL cells
(predominant)
Airway
epithelial mucus
Th1 Neutrophils
 
2
 
Th2 Eosinophils
 
1
 
DO11.10 Th1 or Th2 cells were transferred into wild-type BALB/c
recipient mice and exposed to inhaled OVA (reference 15). BAL differ-
entials were performed on cytospin samples, and lung sections were an-
alyzed for mucus staining. 
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philia and mucus production and if Th1 cells could inhibit
Th2-induced inflammation, we performed mixing experi-
ments by transferring both Th1 and Th2 cells together into
recipient mice. Th1 and Th2 cells were each generated in
vitro from CD4 T cells isolated from TCR-transgenic,
DO11.10 mice that were cultured with APCs, pOVA
 
323–339
 
,
and polarizing cytokines as previously described (15). At the
time of transfer, Th1 cells secrete high levels of IFN-
 
g
 
 and
no IL-4 and IL-5, whereas Th2 cells produce very low lev-
els of IFN-
 
g 
 
but high levels of IL-4 and IL-5 (Fig. 1).
Mice received transfer of Th1, Th2, or a mixture of Th1
and Th2 cells (Th1 
 
1
 
 Th2) and were exposed to inhaled
antigen. Airway eosinophilia, which is consistently present
after transfer of Th2 cells and exposure to inhaled OVA, is
markedly reduced when Th1 
 
1
 
 Th2 cells are transferred
(Fig. 2). The inhibitory effects of Th1 cells on airway eosino-
philia are dependent on the number of Th1 cells transferred,
as when fewer Th1 cells are transferred into the mice, more
eosinophils are present in the BAL. When equal numbers of
Th1 and Th2 cells were transferred together and mice were
exposed to inhaled antigen, eosinophils were consistently in-
hibited sevenfold or greater in experiments that employed
transfer of a range of different cell numbers (10
 
6
 
–5 
 
3
 
 10
 
6
 
cells). Mice exposed to inhaled OVA after no cells were
transferred or after Th1 cells were transferred did not ex-
hibit BAL eosinophilia.
Th2 cells induce a marked increase in mucus staining in
the bronchial epithelium, but when Th1 
 
1
 
 Th2 cells are
transferred, there is a reduction in airway epithelial mucus
staining (Fig. 3). This inhibition of mucus staining in the
airway epithelium is modest when airway inflammation is
severe (after transfer of 2.5 
 
3
 
 10
 
6
 
 cells). When fewer Th2
cells are transferred into recipient mice, resulting in less in-
flammation, mucus staining is markedly inhibited by equal
numbers of Th1 cells (Fig. 3). When two times the number
of Th1 cells are transferred with Th2 cells (2:1), there is
complete inhibition of mucus staining. Thus, Th1 cells in-
hibit Th2-induced mucus in a dose-dependent fashion. Mice
that were exposed to inhaled OVA and received transfer of no
cells or Th1 cells showed mucus staining in 
 
,
 
5% of bronchial
 
epithelial cells. Therefore, when Th1 and Th2 cells are trans-
ferred together into recipient mice, Th1 effects dominate,
resulting in the inhibition of Th2-induced airway eosino-
philia and mucus production.
 
IFN-
 
g
 
– and IL-4–producing Cells Are Present in the Airways
after Transfer of Th1 and Th2 Cells, but Inflammation Is Not
Increased.
 
It was possible that Th1 cell inhibition of Th2-
Figure 1. Cytokine production by Th1 or Th2 cells. At the time of
transfer into recipient mice, in vitro–generated DO11.10 CD4 Th1 or Th2
cells were cultured with APCs in the presence of pOVA323–339. Superna-
tants were collected after 48 h, and cytokine ELISAs were performed. One
experiment is shown and is representative of five experiments.
Figure 2. Effects of Th1 cells on airway eosinophilia. Th1, Th2, or Th1 1
Th2 cells (numbers shown) were transferred into BALB/c recipient mice,
and mice were exposed to inhaled OVA for 7 d. 24 h later, mice were
killed and BAL was performed. Total cell and differential counts were
performed on cells recovered from BAL in individual mice. Data repre-
sents mean number of BAL eosinophils (6SEM) (n 5 4 mice per group).
One experiment is shown and is representative of four experiments. Sta-
tistical significance was determined by unpaired Student’s t test. *P , 0.05
Th2 versus Th1 (1.25) 1 Th2 (2.5); ‡P , 0.002 Th2 versus Th1 (2.5) 1
Th2 (2.5).
Figure 3. Effects of Th1 cells on airway mucus production. Th1, Th2,
or Th1 1 Th2 cells (numbers shown) were transferred into BALB/c re-
cipient mice, and mice were exposed to inhaled OVA for 7 d. 24 h later,
mice were killed. Mucus staining was assessed on PAS-stained lung sec-
tions. Data represents mean HMI (6SEM) (n 5 4 mice per group). One
experiment is shown and is representative of four experiments. Statistical
significance was determined by unpaired Student’s t test. *P , 0.05 Th2
versus Th1 (2.5) 1 Th2 (2.5). ‡P , 0.0004 Th2 versus Th1 (1.0) 1 Th2
(1.0) or Th1 (2.0) 1 Th2 (1.0). 
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induced inflammation resulted from decreased Th2 cell ac-
tivity, either by blocking recruitment of cells to the lung or
by direct suppression of Th2 cell activation. To determine
if Th2 cells were active in the lungs of mice after transfer of
Th1 
 
1
 
 Th2 cells, we examined BAL fluid recovered after
transfer of cells and exposure to inhaled OVA. In mice that
received Th1 
 
1
 
 Th2 cells and inhaled OVA, IL-4, IL-5,
and IL-13 were present in the BAL fluid at levels compara-
ble to those in BAL fluid recovered from mice that were
exposed to OVA after transfer of Th2 cells alone (Fig. 4).
IFN-
 
g
 
 levels were similar in mice that received Th1 
 
1
 
Th2 cells or Th1 cells alone and inhaled OVA. BAL cells
recovered from mice after exposure to inhaled OVA and
transfer of Th1 
 
1
 
 Th2 cells produced IL-4, IL-5, IL-13,
and IFN-
 
g
 
 (data not shown), again indicating that both the
transferred, OVA-responsive DO11 Th1 and Th2 cells are
present in the respiratory tract. These data suggest that Th1
inhibition of Th2-induced inflammation does not result from
inhibition of Th2 cell activation in the respiratory tract but
 
at steps downstream of cytokine secretion.
In mice that received Th1 
 
1
 
 Th2 cells and inhaled OVA,
airway inflammation, as measured by the total number of
BAL cells recovered from mice, was not increased when
compared with mice that received Th2 cells and inhaled
OVA (Table II). This was independent of the number of
transferred cells, as shown. These data indicate that cotransfer
of Th2 and Th1 cells, doubling the number of transferred
cells, does not lead to increased airway inflammation yet results
in suppression of airway eosinophilia and mucus induction.
 
Eosinophilia Is Dependent on Th2 Cells and Is Inhibited by
IFN-
 
g
 
.
 
To determine the mechanism by which Th1 cells
inhibit Th2-induced inflammatory responses, we investi-
gated the role of the Th1 cytokine IFN-g, as IFN-g had been
shown previously to have inhibitory effects on Th2 cell func-
tions in vivo, including inhibition of CD4 T cell migration,
eosinophilia, and IgE production (26–29). We transferred
DO11 Th1, Th2, or Th1 1 Th2 cells into IFN-gR1/1 or
IFN-gR2/2 mice. Although the transferred DO11 Th1 cells
were able to secrete IFN-g at the time of transfer, IFN-gR2/2
recipient mice were unable to respond to IFN-g. After ex-
posure to inhaled OVA, IFN-gR2/2 mice that received
Th1 1 Th2 cells showed marked airway eosinophilia,
with levels of eosinophils equivalent to those in IFN-gR2/2
mice that received transfer of Th2 cells and inhaled OVA
(Fig. 5). Thus, Th1 cells no longer inhibited Th2-induced
eosinophilia in the absence of IFN-g signaling. IFN-gR1/1
mice that received transfer of the same population of Th1 1
Th2 cells had 18-fold fewer eosinophils in the BAL. After
transfer of Th2 cells and exposure to inhaled antigen, IFN-
gR2/2 recipients had four times as many eosinophils in the
BAL than IFN-gR1/1 recipients, indicating that even
during heavily skewed Th2 responses, the inhibitory effects
of IFN-g on airway eosinophilia are present. IFN-gR2/2
mice that received Th1 cells and inhaled OVA or mice that
received inhaled OVA alone did not exhibit significant
eosinophilic airway inflammation. Therefore, the induction
Figure 4. Cytokine levels in BAL fluid after inhaled antigen exposure.
After transfer of Th1, Th2, or Th1 1 Th2 (2.5 3 106 cells from each
population) and exposure to inhaled antigen, BAL fluid was collected and
cytokines were measured by ELISA. The mean cytokine level (6SEM) is
shown (n 5 3 mice per group).
Table II. Airway Inflammation in Mice after Inhaled Antigen Challenge
Cells transferred
Total BAL cells
BAL cell differential
Type Number Eosinophils PMNs Lymphocytes Macrophages
3106 3105 % (6SE) % (6SE) % (6SE) % (6SE)
Experiment 1
Th1 5 5.7 (1.7) 0 (0) 21 (2) 37 (7) 42 (6)
Th2 5 5.3 (0.4) 35 (9) 3 (1) 37 (4) 25 (6)
Th1 1 Th2 5 1 5 5.9 (1.2) 3 (1) 23 (1) 39 (5) 35 (4)
Experiment 2
Th1 2.5 2.9 (0.4) 0 (0) 37 (3) 43 (4) 20 (2)
Th2 2.5 8.3 (1.9) 36 (2) 5 (1) 31 (3) 28 (2)
Th1 1 Th2 2.5 1 2.5 3.5 (0.5) 1 (0) 23 (3) 44 (1) 32 (3)
DO11.10 Th1, Th2, or Th1 1 Th2 cells were transferred into wild-type BALB/c recipient mice, and mice were exposed to inhaled OVA. Total
cell and differential counts were performed on BALs. Cell counts are shown (6SE).1313 Cohn et al.
of airway eosinophilia requires activated Th2 cells and can
be inhibited by IFN-g secreted by Th1 cells.
Mucus Production Is Not Inhibited by Th1 Cells in IFN-gR2/2
Mice. When Th1 1 Th2 cells are transferred into IFN-
gR2/2 mice and mice are exposed to inhaled OVA, mucus
staining is present at levels similar to mucus staining in
IFN-gR2/2 mice that received Th2 cells alone (Fig. 6). Th1
cell inhibition of Th2-induced mucus is no longer present
in IFN-gR2/2 mice, suggesting that IFN-g inhibits mucus
production by airway epithelial cells. Yet when Th1 cells
were transferred into IFN-gR2/2 mice and mice were ex-
posed to inhaled OVA, mucus was also induced (Fig. 6), in-
dicating that Th1 cells are capable of inducing mucus when
IFN-g signaling is absent. IFN-g not only inhibits Th2-
induced mucus production, but the absence of mucus in
IFN-gR1/1 animals that received Th1 cells (Fig. 3) appears
to be a result of active inhibition by IFN-g. These data sug-
gest that Th2 cells are not essential for mucus induction.
It was still possible that the induction of mucus produc-
tion by DO11 Th1 cells in IFN-gR2/2 mice was a result of
Th2 cytokine activation, as blockade of IFN-g during a Th1
cell response can induce the cell population to produce IL-4
(30). To test if the cytokine pattern of the DO11.10 Th1
population had shifted in vivo, we harvested BAL cells from
mice that received Th1 cells and inhaled OVA and restim-
ulated the cells in vitro with pOVA323–339. BAL cells recov-
ered from IFN-gR2/2 recipient mice secreted high levels
of IFN-g and minimal IL-4, IL-5, and IL-13, similar to the
levels of cytokines secreted by BAL cells recovered from
IFN-gR1/1 recipient mice (Table III). Thus, Th1 cells, after
recruitment and activation in IFN-gR2/2 mice, remain polar-
ized to Th1 yet are capable of stimulating mucus production.
In summary, airway epithelial mucus production and airway
eosinophilia are stimulated by different mechanisms; recruit-
ment of eosinophils to the airway requires Th2 cells, whereas
mucus can be induced by both Th1 and Th2 cells, as long as
IFN-gR signaling is absent. Despite different mechanisms of
induction, both airway eosinophilia and mucus production
can be inhibited by activation of Th1 cells producing IFN-g.
Inhibition of Airway Mucus and Eosinophilia Requires IFN-gR
in Recipient Mice. Th1 and Th2 cytokines are both present
after transfer of Th1 1 Th2 cells and exposure to inhaled
OVA (Fig. 4), suggesting that the downregulatory effects of
Th1 on Th2 cells are not through direct inhibition of Th2
cell activation. The mechanism of action of Th1 cells is
precisely defined in transfer experiments using IFN-gR2/2
recipient mice (Figs. 5 and 6). In IFN-gR2/2 mice, the
transferred DO11.10 Th2 cells express the IFN-gR and are
Figure 5. Airway eosinophilia induced in IFN-gR2/2 mice. Th1,
Th2, or Th1 1 Th2 cells (2.5 3 106 cells from each population) were
transferred into IFN-gR1/1 (BALB/c) or IFN-gR2/2 recipient mice,
and mice were exposed to inhaled OVA. Total cell and differential counts
were performed on cells recovered from BAL in individual mice. Data
represents mean number of BAL eosinophils (6SEM) (n 5 4 mice per
group). One experiment is shown and is representative of two experi-
ments. Statistical significance was determined by unpaired Student’s t test.
*P , 0.0001 Th2 versus Th1 1 Th2.
Figure 6. Airway mucus production in IFN-gR2/2 mice. Th1, Th2,
or Th1 1 Th2 cells (2.5 3 106 cells from each population) were trans-
ferred into IFN-gR1/1 (BALB/c) or IFN-gR2/2 recipient mice, and
mice were exposed to inhaled OVA. Mucus staining was assessed on
PAS-stained lung sections. Data represents mean HMI (6SEM) (n 5 4
mice per group). One experiment is shown and is representative of two
experiments. Statistical significance was determined by unpaired Student’s
t test. *P , 0.0004 Th2 versus Th1 1 Th2.
Table III. Cytokine Production by BAL Cells Recovered from 
Mice after Transfer of Th1 Cells
Transferred
cells
Recipient
mice IFN-g IL-4 IL-13 IL-5
ng/ml ng/ml ng/ml ng/ml
Th1 IFN-gR1/1 2,138 0 0.3 0
Th1 IFN-gR2/2 1,084 (425) 0 0.6 (0.3) 0
BAL cells were recovered from mice after transfer of 2.5 3 106 Th1
cells and exposure to inhaled OVA. Cells were restimulated in vitro
with pOVA323–339 for 48 h, and cytokine ELISAs were performed on
supernatants. In IFN-gR2/2 mice, mean cytokine production is shown
(6SE) (n 5 3 mice per group). In IFN-gR1/1 recipient mice, BAL
cells from three mice were pooled.1314 Th1 Cells Regulate Allergic Airway Inflammation and Mucus Production
capable of responding to IFN-g secreted by Th1 cells. If Th1
cells were directly blocking Th2 cell function, then inhibi-
tion of eosinophilia and mucus production would persist in
IFN-gR2/2 mice. Yet the inhibitory effects of Th1 cells on
Th2 cell–induced eosinophilia and mucus production are
completely abolished in IFN-gR2/2 mice. These studies sug-
gest that IFN-g produced by Th1 cells inhibits Th2-induced
eosinophilia and mucus production despite ongoing Th2
cytokine secretion, through effects requiring IFN-gR in re-
cipient mice. As different inflammatory pathways stimulate
airway eosinophilia and mucus production, it is likely that
IFN-g inhibits these processes through distinct mechanisms
that are induced in target tissue.
Discussion
Recent studies have established that CD4 Th2 cells and
their cytokines initiate an inflammatory response in the re-
spiratory tract with many features of asthma. In contrast, Th1
cells lead to inflammation but exhibit none of the asthmatic
pathology. As both Th1 and Th2 cells have been identified
in the lungs of asthmatic patients, we investigated whether
Th1 cells could regulate allergic airway pathology. In this
report, we show that coactivation of Th1 and Th2 cells in
the lung leads to a dominance of Th1 effects, inhibiting both
airway eosinophilia and mucus production. Th1 cells, through
the production of IFN-g, inhibit these Th2-induced effects,
not by regulating Th2 cell activity, as previously suggested,
but by blocking downstream pathways induced by Th2 cy-
tokines. Furthermore, the marked inhibitory effects of Th1
cells occur without an increase in airway inflammation. Thus,
it appears that Th1 cells block critical pathologic changes
that contribute significantly to morbidity and mortality in
asthma. Our data show that IFN-g inhibits airway eosino-
philia even during polarized Th2-type responses, indicating
that Th1 cells in the airways of asthmatics may be active in
controlling disease.
In addition, these studies are the first to show that the
development of inflammatory pathology in asthma can be
differentially controlled. Whereas airway eosinophilia de-
pends on the presence of activated Th2 cells in the lung, mu-
cus can be induced by different types of inflammatory infil-
trates as long as IFN-gR signaling is blocked. Th1 cells fail
to stimulate mucus because IFN-g inhibits its production.
Th1 cells do not induce eosinophilia, most likely due to a
lack of IL-5 (31).
Th1 responses have been proposed to protect against
asthma. This theory is based on Th2-dominant lymphocyte
populations in the airways of asthmatics and evidence that
Th1 responses protect in asthmatics and in animal models
of asthma (2, 7, 11–13). Th1 cells may inhibit Th2 cell func-
tion at different stages in the effector response. Th1 cells,
through the production of IFN-g, have been shown to in-
hibit Th2 cell cytokine production and Th2 cell prolifera-
tion in vitro (32, 33). In mice, the Th1 cytokine IFN-g has
inhibitory effects on Th2-induced airway eosinophilia and
AHR. When administered before inhaled antigen challenge,
IFN-g reduced the number of CD4 T cells in the respira-
tory tract (26, 28, 29) or reduced Th2 cytokine secretion
(26, 34). These effects may result from inhibition of Th2
cell recruitment by IFN-g. Once Th2 cells are present in
the respiratory tract, IFN-g suppresses the resolution of
Th2-induced inflammation, as shown in IFN-gR2/2 mice
that had prolonged eosinophilia and Th2 cytokine produc-
tion (35). In this report, we show another role of IFN-g in
the regulation of Th2 responses. Th1 cell production of
IFN-g blocks Th2-induced inflammatory pathways down-
stream of cytokine production. This may occur by direct
effects on eosinophils and epithelial cells or through an in-
termediate cell derived from the recipient mice. This mecha-
nism of inhibition is of potential importance in asthmatic
airways, where Th2 cells are chronically present, as we show
that Th1 cells can inhibit Th2 cell effects while Th2 cells
are actively secreting cytokines.
The inhibitory pathways induced by Th1 cells require
more than a few days for induction. In our studies, the in-
hibitory effects of Th1 cells were seen in mice exposed to
antigen over 9 d. These effects were not observed when we
killed mice after just 2 d of antigen challenge: BAL eosino-
philia was similar after transfer of Th2 cells or Th1 1 Th2
cells and inhaled antigen (data not shown). It is possible
that a short period of antigen exposure explains, in part, why
other investigators did not observe a similar reduction in
eosinophilia after recruitment and activation of Th1 and Th2
cells in the respiratory tract (36, 37). This delay in inhibition
of eosinophilia and mucus production by Th1 cells may
point to a biological pathway that requires either time or
stimulation with higher levels of IFN-g to induce inhibition.
In defining the functional effects of Th1 cells on Th2-
mediated airway inflammation, our studies provide insights
into potential mechanisms governing symptom control in
conventional allergy immunotherapy. These mechanisms
need to be analyzed, as we have shown, by assessing the
lymphocyte populations present at sites of inflammation where
cytokines exert their effects. Studies of grass pollen immuno-
therapy for atopic skin disease and allergic rhinitis showed a
reduction in late phase responses and eosinophil accumula-
tion in the skin and nasal mucosa. These effects were asso-
ciated with increased IFN-g–expressing cells, yet cells posi-
tive for IL-4 and IL-5 were unchanged (9, 10). In addition,
persistent Th2 cytokine production with increased IFN-g–
producing cells may explain why IgE levels and skin prick
testing were not reduced, but IgG1/IgG4 levels increased
in successful immunotherapy of pollen-allergic individuals
(38). Increasing the population of activated Th1 cells at sites
of allergic inflammation should be a focus of new techniques
of immunotherapy, as IFN-g can exert its effects despite
ongoing Th2 cell activation. These effects may be sustained,
as there is evidence that potent, long-term stimulation with
Th1 cytokines can shift a Th2-predominant population to-
ward Th1 (39–41).
Increasing Th1 cell activation during immunotherapy in
asthma bears the potential risk of increasing inflammation.
Successful immunotherapy for atopic skin disease and rhinitis
in allergic patients has not borne out these concerns (10, 41).
In our studies and others, airway inflammation was not in-1315 Cohn et al.
creased when both Th1 and Th2 cells were recruited to the
lung in wild-type recipient mice (42). This may relate to
normal regulation of T cell proliferation that is typically
present in intact, immunocompetent mice (43). Hansen et
al. (42) showed that Th1 and Th2 cells transferred into SCID
mice, which lack these regulatory elements, leads to unre-
strained proliferation and overwhelming airway and paren-
chymal inflammation. Furthermore, reducing airway eosin-
ophilia leads to a reduction in tissue damage and cellular
infiltration (44–46). Blocking recruitment of eosinophils to
the airway results in a reduction in proinflammatory factors
that potentiate inflammation. Thus, as these studies show,
the net effect of recruiting Th1 cells to the lung is that total
inflammation is relatively unchanged.
Airway inflammation has long been associated with ex-
cess mucus production. In chronic bronchitis, cystic fibrosis,
and asthma, mucus hypersecretion is associated with differ-
ent characteristic immune responses in the lung. Unlike
asthmatics, patients with cystic fibrosis or chronic bronchi-
tis typically do not show activated Th2 cells in their air-
ways. In a model of asthma, we recently showed that Th2
cells stimulate airway mucus production (15). Mucus in-
duction requires IL-4Ra but is independent of IL-4, IL-5,
eosinophils, and mast cells (47). Other recent studies
showed that IL-13 and IL-4 are important mediators in
mucus production (48–52). Here we also show that Th1
cells stimulate mucus production in the absence of IFN-gR
signaling. The neutrophil-predominant inflammatory re-
sponse in these mice and the relationship of neutrophilia
with mucus hypersecretion in cystic fibrosis and chronic
bronchitis suggests that neutrophils may be involved in
mucus hyperproduction. Neutrophil elastase is a potent
mucus secretagogue (53), yet the ability of this enzyme to
stimulate increased mucin production has not been deter-
mined. We have shown that mucus induction is not due to
a shift of the transferred Th1 cell population to a Th2 phe-
notype in IFN-gR2/2 recipient mice. There still remains
the possibility that very low levels of IL-13 secreted by Th1
cells stimulate mucus production in IFN-gR2/2 mice. In
summary, we have shown that mucus can be induced by an
inflammatory response that is not dominated by production
of IL-13 and IL-4.
Although different inflammatory responses stimulate mu-
cus production, Th1 cells, through production of IFN-g, in-
hibit mucus induced by both Th1 and Th2 cells. Inhibitory
pathways for mucus have not been previously demonstrated.
IFN-g has been shown to have inhibitory effects on some
epithelial functions. In gastric epithelial cells, mucus secretion
was inhibited by IFN-g (53). IFN-g also inhibited growth of
a human bronchial epithelial cell line and reduced barrier
function and chloride secretion in intestinal epithelial cells
(54, 55). Beyond these limited studies, the inhibitory effects
of IFN-g on airway epithelium are not known. Interestingly,
mucus production is not a feature of Th1-mediated pulmo-
nary diseases in humans. Mycobacterium tuberculosis infec-
tion and sarcoidosis are diseases in which IFN-g–produc-
ing CD4 T cells have been identified in the lung biopsies
and in BAL (56–58). It is possible that the lack of mucus
production in these conditions results from IFN-g suppres-
sion. IFN-g has many proinflammatory effects in the lung,
most notably on macrophages, activating production of
reactive nitrogen and oxygen species. The inhibitory effects
of IFN-g could therefore be through the production of in-
hibitory mediators by inflammatory cells or by direct effects
on goblet cells. These studies establish the first known natu-
ral inhibitor of mucus production, one that can be active in
different inflammatory settings.
In summary, using a transfer system that we developed to
study the role of CD4 Th1 and Th2 cells in airway disease,
we have defined two different pathways by which Th1 cells
can regulate airway inflammation. Th1 cells, through an ef-
fect mediated by IFN-gR, block the recruitment of eosino-
phils to the airway and inhibit airway epithelial mucus pro-
duction. In the absence of IFN-gR, Th1 cells induce mucus
production but do not stimulate airway eosinophilia. Thus,
Th1 cells have differential effects on stimulating these in-
flammatory responses. The inability of Th1 cells to stimulate
eosinophilia likely results from a lack of IL-5. The mechanism
by which mucus production is stimulated by Th1 cells in
the absence of IFN-gR signaling is not yet known. As we
learn how these inflammatory responses are regulated, we
will identify new targets for directed immunotherapy for
asthma and mucus hypersecretion.
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